Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone

Απλή σελίδα τεκμηρίου
dc.contributor.authorAlymara, V.en
dc.contributor.authorBourantas, D.en
dc.contributor.authorChaidos, A.en
dc.contributor.authorBouranta, P.en
dc.contributor.authorGouva, M.en
dc.contributor.authorVassou, A.en
dc.contributor.authorTzouvara, E.en
dc.contributor.authorBourantas, K. L.en
dc.date.accessioned2015-11-24T19:22:07Z
dc.date.available2015-11-24T19:22:07Z
dc.identifier.issn1466-4860-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22145
dc.rightsDefault Licence-
dc.subjectAdministration, Oralen
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectDeferoxamine/*administration & dosage/adverse effectsen
dc.subjectDose-Response Relationship, Drugen
dc.subjectDrug Administration Scheduleen
dc.subjectDrug Therapy, Combinationen
dc.subjectFemaleen
dc.subjectFerritins/blood/drug effectsen
dc.subjectHumansen
dc.subjectInjections, Subcutaneousen
dc.subjectIron/urineen
dc.subjectIron Chelating Agents/*administration & dosage/adverse effectsen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPyridones/*administration & dosage/adverse effectsen
dc.subjectTreatment Outcomeen
dc.subjectbeta-Thalassemia/*drug therapyen
dc.titleEffectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiproneen
heal.abstractINTRODUCTION: The purpose of our study was to evaluate the effectiveness and safety of combined therapy with deferoxamine (DFO) and deferiprone (DFP) in patients with beta-thalassemia major and increased serum ferritin. PATIENTS AND METHODS: Our study was performed in 36 patients with beta-thalassemia major. DFP was administered orally in a total daily dose of 60 mg/kg for 6 days per week and DFO was administered subcutaneously in a total daily dose of 40-50 mg/kg for 4-6 days per week. The efficacy of combined treatment was assessed by measurements of serum ferritin and 24-h urine iron excretion levels. RESULTS: Out of the 36 patients, 11 discontinued DFO after a mean of 4 months; however, 25 patients, who continued to receive the combined therapy showed a very satisfactory compliance. After a mean of 13.5 months, their mean serum ferritin levels reduced from 2637 + 1292 to 1580 + 1024 ng/ml (P = 0.002) and their mean urinary iron excretion elevated from 0.41 + 0.27 to 0.76 +0.49 mg/24h (P = 0.003). The observed side effects were gastrointestinal disorders,elevations in liver enzymes, mild neutropenia, joint symptoms, taste disorders, dizziness and fatigue. CONCLUSIONS: The results of this study show that combined iron-chelation therapy with DFO and DFP results in satisfactory reduction of serum ferritin with no significant toxicity.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1038/sj.thj.6200550-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15570288-
heal.journalNameHematol Jen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2004-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ